| Objective: To investigate the acute phase research of Urinary Kallidinogenase on neurological function,RBC deformation and Hs-CRP in stroke in progression(SIP).And to approch the curative effect of Urinary Kallidinogenase in acute phase of SIP,in order to provide clinic foundation for the clinical therapy of SIP.Methods: 50 patients with stroke in progressive(SIP) were treated by the Second Affiliated Hospital of Dalian Medical University during December 2007 to November 2008.Fifty patients with progressive cerebral infarction were randomly divided into the groups treatment and control. Both groups were given the discretion to reduce intracranial pressure, control of cerebral edema,control of blood glucose,blood pressure adjust- ment,removal of free radicals,promoting blood circulation and maintain water-electrolyte balance and prevention and cure infection,such as sym- ptomatic treatment and low molecular heparin subcutaneous injection. Human Urinary Kallidinogenase was administrated to the patients in the treatment group for 7 days in addition to the basic therapy.All the patients have been evaluated by NIHSS and hemorheology and Hs-CRP at the prior treatment and at day 7 after initiating the therapy.Results:1. Control group of prior treatment, NIHSS score was 5.40±0.44; treatment group of prior treatment NIHSS score was 5.28±0.42.The difference between two groups was not statistically significant (P>0.05).After 7 days,control group NIHSS score was 4.00±0.44;treatment group NIHSS score was 2.72±0.38.Difference between the two groups was significant (P<0.05).2. After 7 days,control group,one cases of patients was cured,s- igni- ficant progress in 7 patients,the progress of eight cases of patients, ineffective in patients with 6 cases,the deterioration of three cases of patients,death 0 cases,the effective rate was 32%;treatment group cured three cases of patients,patients with significant progress in 15 cases,three cases of patients with progressive,three cases of patients with null and void,the deterioration of patients with one cases,death 0 cases,the effective rate was 72%.3. Before treatment,erythrocyte deformability index of control group was 0.98±0.12;erythrocyte deformability index of treatment group was 1.00±0.14.The difference between two groups was not statistically signify- cant (P>0.05).After 7 days,erythrocyte deformability index of control group was 0.98±0.13;erythrocyte deformability index of treatment group was 1.03±0.19.After treatment Difference between the two groups was signi- ficant (P<0.05).4. Before treatment,Hs-CRP of control group was 1.90mg/ul;Hs-CRP of treatment group was 1.83mg/ul.The difference between two groups was not statistically significant (P>0.05).After 7 days, Hs-CRP of control group was5.54mmol/L;Hs-CRP of treatment group was 1.67mg/ul.After treatment,Hs-CRP of control group was higher than before treatment;Hs-CRP of treatment group than before treatment had no obvious changes.After treatment Difference between the two groups was significant (P<0.05).Conclusion:1. Patients with SIP,whose condition had deteriorated ,after the application of Urinary Kallidinogenase can improve the patients with neurological function in acute phase, and promote the rehabilitation of patients.The effective rate was 72%. Efficient than low domestic research, taking medication is not the time of this study except for a shorter and less number of cases.2. Urinary Kallidinogenase able to increase erythrocyte deformability,reduce blood viscosity,and maintain cerebral blood flow fluency and cerebral microcirculation in normal perfusion to control further deterioration in SIP.There was no increase in erythrocyte deformability in clinical research reports.The clinical effects of Urinary Kallidinogenase in erythrocyte deformability and blood viscosity remains to be further study. 3. Urinary Kallidinogenase can control patients with SIP whose Hs- CRP further increase in acute stage,to mitigate the inflammatory response, to reduce brain edema and neuronal damage.Urinary Kallidino- genase play a neuroprotective effect.There is no clinical report about Urinary Kal- lidinogenase on the impact of Hs-CRP.Urinary Kallidinogenase whether can be controlled by controlling the acute phase in SIP with Hs-CRP further increased, thereby improving the prognosis of the acute stage for further clinical research.
|
PDF Full Text Request